Sabby Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Sabby Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-6,262	Closed	-$4.27M	–	201
2020 Q4	$4.27M	Buy	+6,262	New	+$50.3K	0.82%	24
2020 Q3	–	Sell	-5,155	Closed	-$3.24M	–	156
2020 Q2	$3.24M	Buy	+5,155	New	+$19.7K	0.65%	25
2016 Q4	–	Sell	-164	Closed	-$127K	–	337
2016 Q3	$127K	Buy	+164	New	+$1.1K	﹤0.01%	286
2015 Q4	–	Sell	-2,275	Closed	-$1.91M	–	387
2015 Q3	$1.91M	Buy	+2,275	New	+$36.2K	0.08%	163

Other funds holding SRNE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Sabby Management's SRNE Position: Q1 2022 in Review

Sabby Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2022, closing a stake of 2,189,700 shares — an estimated $10.2M sold.

Sabby Management first reported a position in SRNE in Q4 2013 and held it in 15 quarters. The position peaked at $13M in Q3 2021. 235 funds tracked by Wall St. Rank hold SRNE as of Q1 2022.

Sabby Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
Sabby Management sold 2,189,700 Sorrento Therapeutics, Inc. shares in Q1 2022, an estimated $10.2M.
Sabby Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2013 and held it in 15 quarters.
Sabby Management's Sorrento Therapeutics, Inc. position peaked at $13M in Q3 2021.
235 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2022.

Based on Sabby Management's 13F filing for Q1 2022, filed 16 May 2022.